Please login to the form below

Not currently logged in
Email:
Password:

Docetaxel

This page shows the latest Docetaxel news and features for those working in and with pharma, biotech and healthcare.

Merck/Pfizer’s cancer immunotherapy latecomer hits a snag

Merck/Pfizer’s cancer immunotherapy latecomer hits a snag

Bavencio did not meet the objective of improving overall survival compared to chemotherapy drug docetaxel as a second-line therapy in NSCLC patients with PD-L1-expressing tumours who had seen

Latest news

More from news
Approximately 1 fully matching, plus 120 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics